Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01943565 · ClinicalTrials.gov registry record · Phase 4
Intrathecal Hydromorphone for Post-cesarean Delivery Pain - a Dose Finding Study
A Phase 4 study, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 29
- Enrollment target
NCT01943565 is a Phase 4 study that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 29 participants.
The verdict
NCT01943565, a Phase 4 study, was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 29 participants
- Enrollment target
Study Summary
Pain relief after cesarean delivery can be provided in a few ways. Most commonly, certain medications called opioids, such as morphine, are given through the vein or into the muscle. However, a more effective way to give pain relief with fewer side effects (such as nausea and slowing your breathing) is to give opioids in the spinal space as part of the medications given for a cesarean delivery. For many years, the opioid of choice was morphine due to its long anesthetic effect and acceptable side effect profile. A nation-wide disruption in the supply of preservative-free morphine has made it necessary to look for alternatives. Many institutions worldwide have used another opioid, called hydromorphone, in the spinal space for over a decade. This drug has a very good safety and side effect profile and has been used at the investigators' institution for more than a year. Of interest, while a number of different doses of hydromorphone have been used, there have been very few studies to evaluate the best dose for providing good pain relief with minimal side effects. The goal of this study is to find the best dose of spinal hydromorphone for women undergoing cesarean delivery.
Interventions
- DRUG Hydromorphone 25mcg
- DRUG Hydromorphone 50mcg
- DRUG Hydromorphone 100mcg
- DRUG spinal anesthesia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2014-12 |
| Est. Completion | 2016-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01943565
The ClinicalTrials.gov registry entry for NCT01943565 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Hydromorphone 25mcg is the first listed.
NCT01943565 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01943565 about?
NCT01943565 is a clinical study titled "Intrathecal Hydromorphone for Post-cesarean Delivery Pain - a Dose Finding Study". Pain relief after cesarean delivery can be provided in a few ways. Most commonly, certain medications called opioids, such as morphine, are given through the vein or into the muscle. However, a more effective way to give pain relief with fewer side effects (such as nausea and slowing your breathing)...
What is the current status of trial NCT01943565?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 29 participants. The study started on 2014-12. Estimated completion is 2016-08.
What interventions are being tested in trial NCT01943565?
The interventions under investigation include: Hydromorphone 25mcg (DRUG), Hydromorphone 50mcg (DRUG), Hydromorphone 100mcg (DRUG), spinal anesthesia (DRUG).
Who is sponsoring clinical trial NCT01943565?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.